GKOS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 16:00):

Stats
Today's Volume	281 764
Average Volume	685 956
Market Cap	4.79B
EPS	$0 ( 2024-02-21 )
Next earnings date	( $-0.590 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.85
ATR14	$0.0880 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Hoffmeister David F	Buy	10 000	Common Stock
2024-04-10	Hoffmeister David F	Sell	10 000	Stock Option (Right to Buy)
2024-04-08	Gilliam Joseph E	Buy	59 801	Common Stock
2024-04-08	Gilliam Joseph E	Sell	10 456	Common Stock
2024-04-08	Gilliam Joseph E	Sell	41 068	Common Stock

INSIDER POWER
0.85
Last 100 transactions
Buy: 501 923 \| Sell: 495 631

Volume Correlation

Long: -0.37 (neutral)

Short: -0.94 (very strong negative)

Signal:(32.817) Neutral

Glaukos Corp Correlation

10 Most Positive Correlations
HDIV	0.826
LXFR	0.808
NXN	0.804
BFS-PD	0.803

10 Most Negative Correlations
FORG	-0.813

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Glaukos Corp Correlation - Currency/Commodity

-0.17
( neutral )

0.49
( neutral )

-0.58
( weak negative )

-0.59
( weak negative )

-0.45
( neutral )

0.66
( moderate )

Glaukos Corp Financials

Annual	2023
Revenue:	$314.71M
Gross Profit:	$239.14M (75.99 %)
EPS:	$-2.78

Q4	2023
Revenue:	$82.37M
Gross Profit:	$63.47M (77.06 %)
EPS:	$-0.750

Q3	2023
Revenue:	$78.05M
Gross Profit:	$59.54M (76.28 %)
EPS:	$-0.630

Q2	2023
Revenue:	$80.40M
Gross Profit:	$60.30M (75.00 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Glaukos Corp

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.